H.Res. 685 is a non-binding resolution expressing the House of Representatives' support for adding antiphospholipid syndrome (APS) testing to standard prenatal screening. APS is an immune system condition that increases the risk of blood clots and can lead to miscarriages, stillbirths, and other pregnancy complications; it accounts for about 15 percent of recurrent pregnancy losses but currently is only tested after multiple unexplained losses occur. The resolution calls on professional medical organizations and guideline-setting bodies to update their recommendations to include routine APS testing during pregnancy, noting that the condition can be easily detected with a blood test and treated with blood thinners. The bill contains no funding or implementation timeline since it is a resolution expressing support rather than legislation that mandates action. Sponsored by Representatives Cammack and others, this resolution aims to raise awareness about a treatable condition that could potentially prevent pregnancy loss if identified early.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.